Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Q2 2025 Earnings Presentation
14 slides from Genedx's earnings presentation, Jul 29, 2025
Slide 1: GeneDx 2Q 2025 Earnings Presentation
GeneDx (Nasdaq: WGS) 2Q 2025 Earnings Presentation July 29, 2025
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance, future operations, plans, objectives of management, and our market opportunity, including our expected fu
Slide 3: We envision a world where any genetic disorder is diagnosed early
We envision a world where any genetic disorder is diagnosed as early as possible to prevent disease progression and ensure long and healthy lives for all. 3 Confidential & Proprietary. Do Not Distribute.
Slide 4: We prevent the unnecessary diagnostic journey
We prevent the unnecessary diagnostic journey On average: 16 tests and 5 years before an accurate diagnosis X X X X X X X X X 1 year 3 years 5 years GeneDx provides answers in months weeks days 2 years 4 years hours X X X X X X References: 1. National Orga niza tion for Rare Disord ers (NORD). Hope
Slide 5: We are the leader in diagnosing rare diseases
We are the leader in diagnosing rare diseases First-mover advantage and durable Data unmatched in size, breadth, market leadership and depth • Leader in exome and genome testing • Enriched for rare disease Delivering more rare disease diagnoses than anyone Diagnosing even the rarest conditions for 2
Slide 6: With every patient, we accelerate and widen our competitive advantage
With every patient, we accelerate and widen our competitive advantage Additional patients Higher tested diagnostic yield and more answers for more patients The compounding >850K >7M power of our data exomes & phenotypic informs more diagnoses genomes datapoints and extends our lead. More Improved un
Slide 7: Driving earlier diagnoses
We are increasing market adoption through breadth and depth Increasing the total market opportunity available over time Current Market Market Segment Number of Targets Patient Opportunity Total Future Market Penetration (Patients) Opportunity Newborn Screening Up to 3,600,0001 babies born in the US
Slide 8: Second Quarter 2025 Results
Second Quarter 2025 Results1 Grew revenues to $102.7 million, an increase of 49% 2 year-over-year Grew exome and genome test revenue to $85.9 million, an increase of 69% year-over-year Delivered adjusted gross margin of 71%, up from 62% in the second quarter of 2024 Generated adjusted net income of
Slide 9: Strong exome and genome volume growth, picking up mix share
Strong exome and genome volume growth, picking up mix share • Grew Q2 2025 exome and genome volume 28% year-over-year • Grew mix share for exome and genome to 41% Quarterly Exome and Genome Volume 23,102 Exome and Genome Volume Mix 41% 18,017 31% 22% 11,855 9 Confidential & Proprietary. Do Not Distr
Slide 10: Delivered our fourth consecutive profitable quarter
Delivered our fourth consecutive profitable quarter Quarterly Adj. Net (Loss)/Income 1 (in millions) • Generated second quarter 2025 adjusted net income1 of $15.0 million • Delivered fourth consecutive quarter of adjusted net income1 and second quarter of positive operational cash flow • Cash, cash
Slide 11: Full Year 2025 Guidance
Full Year 2025 Guidance Metric Previous Guidance Updated Guidance Revenue $360 to $375 million $400 to $415 million Growth in exome and genome revenue 30% 48% to 52% Growth in exome and genome volume 30% 30% Adjusted gross margin 66% to 68% 68% to 71% Adjusted net income Positive each quarter and Po
Slide 12: The future of healthcare is about proactive, personalized care
The future of healthcare is about proactive, personalized care. GeneDx is leading the way. 12 Confidential & Proprietary. Do Not Distribute.
Slide 13: Appendix
Appendix 13 Confidential & Proprietary. Do Not Distribute.
Slide 14: Reconciliation of non-GAAP financial measures
Reconciliation of non-GAAP financial measures Adjusted gross profit and adjusted gross margin (in $ thousands) Three months ended June 30 2025 2024 GeneDx Other 1 Total GeneDx Other 1 Total Revenue $ 101,784 $ 908 $ 102,692 $ 68,924 $ 1,590 $ 70,514 Adjusted cost of services 29,964 244 30,208 26,523